05-17-2018 04:07 PM CET - Advertising, Media Consulting, Marketing Research
Print

Antinuclear Antibody Test Market Outlook to 2025: Emerging Trends and Growth Opportunities Status With Analysis & Forecast

Press release from: Data Bridge Market Research
Antinuclear Antibody Test Market Research Analysis 2025
Antinuclear Antibody Test Market Research Analysis 2025
Avail 10% Discount on Direct Purchase "Global Antinuclear Antibody Test Market" Or kindly send the email at sopan.gedam@databridgemarketresearch.com

Global anti-nuclear antibody test market is projected to reach USD 1,964.47 million by 2025 from USD 1,093.40 million in 2017, at a CAGR of 7.7% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Here is the Solution! Click Here For Free Sample Report @: databridgemarketresearch.com/request-a-sample/?dbmr=globa...

Top market players for global anti-nuclear antibody test market are listed below:

• Bio-Rad Laboratories, Inc.
• Alere, Inc.
• Trinity Biotech
• Thermo Fisher Scientific Inc.
• Antibodies Inc.
• EUROIMMUN AG
• Immuno Concepts

ALERE, INC.:

Founded in 2001 and headquartered in Massachusetts, U.S. Alere Inc. operates in rapid diagnostics tests devices. Alere segments are focused on cardiometabolic, infectious disease, and toxicology testing. Alere Inc. offers wide range of diagnostic tests for cardiometabolic disease, and toxicology in the United States and across the globe. The products offered by the company includes rapid diagnostic test systems for diagnosis of point-of-care analyzers and test cassette systems for the blood cholesterol, glucose, and related lipids tests and over-the-counter tests for cholesterol monitoring; blood analysis systems for blood gas, electrolyte, and metabolite testing. The anti-nuclear antibody test products are offered by the test and instruments categories.
Abbott Laboratories acquired Alere which has significantly expanded Abbott’s global diagnostics presence. Alere is operating as a subsidiary of Abbott Laboratories.

Any Specific Requirements? Questions? Ask to Our Industry Expert @ databridgemarketresearch.com/inquire-before-buying/?dbmr=...

BIO-RAD LABORATORIES:

Bio-Rad Laboratories, Inc. founded in 1952 and headquartered in California, U.S. It is engaged in development and production of specialty chemicals used in biochemical, pharmaceutical and other life science research applications. It operates its business through its two business segments life science and clinical diagnostics.

Life Science segment offers the wide range of instruments, software, consumables, reagents, and content for the growing fields of cell biology, gene expression, protein purification, protein quantitation, drug discovery and manufacture, food safety, and science education.
Clinical Diagnostics offers the wide range of innovative products to clinical laboratories worldwide. It has its global presence in over 35 countries.

Market is further segmented into:
• Product
• Test
• Disease
• End-user
The global anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the global anti-nuclear antibody test market with 56.4% market share and is expected to reach USD 1,122.30 million by 2025, with the highest CAGR of 7.9% in the forecast period 2018 to 2025.

The global anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, Indirect Immunofluorescence is expected to dominate the global anti-nuclear antibody test market with 53.3% market share and is expected to reach USD 998.35 million by 2025, with the CAGR of 7.0% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 9.0% in the forecast period, and is expected to reach USD 406.29 million in 2025 from USD 205.60 million in 2017.

Request for Detail Table of Content Visit @ databridgemarketresearch.com/toc/?dbmr=global-antinuclear...

The global anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, Systemic Lupus Erythematosus is expected to dominate the global anti-nuclear antibody test market with 37.6% market share and is expected to reach USD 766.06 million by 2025, at the highest CAGR of 8.3% in the forecast period 2018 to 2025.

The global anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the global anti-nuclear antibody test market with 53.4% market share and is expected to reach USD 1,062.43 million by 2025, at the highest CAGR of 7.9% in the forecast period 2018 to 2025.
Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa.

Based on geography, the global anti-nuclear antibody test market is segmented into geographical regions, such as,
• North- America,
• South America
• Europe
• Asia-Pacific
• Middle East and Africa

Covered in this report

The report covers the present scenario and the growth prospects of the global anti-nuclear antibody test for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Purchase Full Report @ databridgemarketresearch.com/reports/global-antinuclear-a...

TABLE OF CONTENTS GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. INCREASING INCIDENCE OF AUTOIMMUNE DISEASES
3.1.2. RISING MEDICAL INSURANCE
3.1.3. RISE IN GOVERNMENT HEALTHCARE PROTECTION

3.2. RESTRAINTS

3.2.1. STRICT REGULATION FOR PRODUCT APPROVAL

3.3. OPPORTUNITIES

3.3.1. INCREASING GROWTH IN HEALTHCARE EXPENDITURE
3.3.2. EMERGING MARKETS
3.3.3. LABORATORY AUTOMATION FAVORS THE MARKET

3.4. CHALLENGES

3.4.1. LACK OF SKILLED PROFESSIONALS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

6.1. OVERVIEW
6.2. ASSAY KITS & REAGENTS
6.3. SYSTEMS
6.4. SOFTWARE

7. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST

7.1. OVERVIEW
7.2. INDIRECT IMMUNOFLUORESCENCE
7.3. ELISA
7.4. MULTIPLEX TESTING

8. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE

8.1. OVERVIEW
8.2. RHEUMATOID ARTHRITIS
8.3. SYSTEMIC LUPUS ERYTHEMATOSUS
8.4. SJÖGREN’S SYNDROME
8.5. SCLERODERMA
8.6. POLYMYOSITIS
8.7. OTHERS

9. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER

9.1. OVERVIEW
9.2. HOSPITALS
9.3. CLINICS
9.4. PHYSICIAN OFFICE LABORATORIES
9.5. OTHERS

10. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY GEOGRAPHY

10.1. OVERVIEW

10.2. NORTH AMERICA

10.2.1. U.S.
10.2.2. CANADA
10.2.3. MEXICO

10.3. EUROPE

10.3.1. GERMANY
10.3.2. FRANCE
10.3.3. U.K.
10.3.4. ITALY
10.3.5. SPAIN
10.3.6. SWITZERLAND
10.3.7. NETHERLANDS
10.3.8. BELGIUM
10.3.9. RUSSIA
10.3.10. TURKEY
10.3.11. REST OF EUROPE

10.4. ASIA-PACIFIC

10.4.1. CHINA
10.4.2. JAPAN
10.4.3. INDIA
10.4.4. SOUTH KOREA
10.4.5. AUSTRALIA
10.4.6. SINGAPORE
10.4.7. THAILAND
10.4.8. MALAYSIA
10.4.9. INDONESIA
10.4.10. PHILIPPINES
10.4.11. REST OF ASIA-PACIFIC

10.5. SOUTH AMERICA

10.5.1. BRAZIL
10.5.2. REST OF SOUTH AMERICA

10.6. MIDDLE EAST & AFRICA

10.6.1. SOUTH AFRICA
10.6.2. REST OF MIDDLE EAST & AFRICA

11. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, COMPANY LANDSCAPE 220

11.1. COMPANY SHARE ANALYSIS: GLOBAL
11.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
11.3. COMPANY SHARE ANALYSIS: EUROPE
11.4. COMPANY SHARE ANALYSIS: ASIA PACIFIC

12. COMPANY PROFILES

12.1. THERMO FISHER SCIENTIFIC INC.

12.1.1. COMPANY OVERVIEW
12.1.2. THERMO FISHER SCIENTIFIC INC.:REVENUE ANALYSIS
12.1.3. PRODUCT PORTFOLIO
12.1.4. RECENT DEVELOPMENTS

12.2. MERCK KGAA

12.2.1. COMPANY OVERVIEW
12.2.2. MERCK KGAA: REVENUE ANALYSIS
12.2.3. PRODUCT PORTFOLIO
12.2.4. RECENT DEVELOPMENTS

12.3. ALERE INC.

12.3.1. COMPANY OVERVIEW
12.3.2. ALERE INC.: REVENUE ANALYSIS
12.3.3. PRODUCT PORTFOLIO
12.3.4. RECENT DEVELOPMENTS

12.4. TRINITY BIOTECH

12.4.1. COMPANY OVERVIEW
12.4.2. TRINITY BIOTECH: COMPANY OVERVIEW
12.4.3. PRODUCT PORTFOLIO
12.4.4. RECENT DEVELOPMENTS

12.5. ANTIBODIES INC.

12.5.1. COMPANY OVERVIEW

12.5.2. ANTIBODIES INC.: REVENUE ANALYSIS
12.5.3. PRODUCT PORTFOLIO
12.5.4. RECENT DEVELOPMENTS

12.6. BIO-RAD LABORATORIES, INC.

12.6.1. COMPANY OVERVIEW
12.6.2. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
12.6.3. PRODUCT PORTFOLIO
12.6.4. RECENT DEVELOPMENTS

12.7. EUROIMMUN AG (A SUBSIDIARY OF PERKINELMER INC.)

12.7.1. COMPANY OVERVIEW
12.7.2. PERKINELMER INC.: REVENUE ANALYSIS
12.7.3. PRODUCT PORTFOLIO
12.7.4. RECENT DEVELOPMENTS

12.8. IMMUNO CONCEPTS

12.8.1. COMPANY OVERVIEW
12.8.2. IMMUNO CONCEPTS: COMPANY SNAPSHOT
12.8.3. PRODUCT PORTFOLIO
12.8.4. RECENT DEVELOPMENTS

12.9. INOVA DIAGNOSTICS

12.9.1. COMPANY OVERVIEW
12.9.2. INOVA DIAGNOSTICS:COMPANY SNAPSHOT
12.9.3. PRODUCT PORTFOLIO
12.9.4. RECENT DEVELOPMENTS

12.10. ZEUS SCIENTIFIC, INC.

12.10.1. COMPANY OVERVIEW
12.10.2. ZEUS SCIENTIFIC, INC.: COMPANY SNAPSHOT
12.10.3. PRODUCT PORTFOLIO
12.10.4. RECENT DEVELOPMENTS

12.11. MBL INTERNATIONAL

12.11.1. COMPANY OVERVIEW
12.11.2. MBL INTERNATIONAL: COMPANY SNAPSHOT
12.11.3. PRODUCT PORTFOLIO
12.11.4. RECENT DEVELOPMENTS

12.12. MEDSOURCE OZONE BIOMEDICALS PVT. LTD

12.12.1. COMPANY OVERVIEW
12.12.2. MEDSOURCE OZONE BIOMEDICALS PVT. LTD: COMPANY SNAPSHOT
12.12.3. PRODUCT PORTFOLIO
12.12.4. RECENT DEVELOPMENTS

12.13. AESKU GROUP GMBH & CO. KG

12.13.1. COMPANY OVERVIEW
12.13.2. AESKU GROUP GMBH & CO. KG: COMPANY SNAPSHOT
12.13.3. PRODUCT PORTFOLIO
12.13.4. RECENT DEVELOPMENTS

13. RELATED REPORTS

Questions? We’ll Put You On The Right Path Request Analyst Call @ databridgemarketresearch.com/speak-to-analyst/?dbmr=globa...

Related Report

Global Molecular Spectroscopy Market – Industry Trends and Forecast to 2024

Global Molecular Spectroscopy Market, By Type (Nuclear Magnetic Resonance (Continuous Wave, Fourier Transform, Solid State), UV-Vis, Infrared (IR), Near Infrared (NIR), Colour Spectroscopy, Raman Spectroscopy, Others), By Applications (Pharmaceuticals, Biotech, Food and Beverages, Environmental Testing, Academics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Rest of the World) – Industry Trends and Forecast to 2024

databridgemarketresearch.com/reports/global-molecular-spe...

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.
News-ID: 1053720 • Views: 148
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: